InvestorsHub Logo
Followers 87
Posts 33355
Boards Moderated 87
Alias Born 03/22/2005

Re: None

Wednesday, 11/20/2019 9:41:30 AM

Wednesday, November 20, 2019 9:41:30 AM

Post# of 1652
>>> Axsome Therapeutics Inc. (AXSM) Soars 10.78% on November 19


Equities.com

19 November 2019


https://www.equities.com/news/axsome-therapeutics-inc-axsm-soars-10-78-on-november-19


Axsome Therapeutics Inc. is a Axsome Therapeutics Inc is a United States-based healthcare service provider.

Axsome Therapeutics Inc. (AXSM) had a good day on the market for Tuesday November 19 as shares jumped 10.78% to close at $30.43. About 1.81 million shares traded hands on 14,428 trades for the day, compared with an average daily volume of n/a shares out of a total float of 34.51 million. After opening the trading day at $27.77, shares of Axsome Therapeutics Inc. stayed within a range of $30.55 to $27.73.

With today's gains, Axsome Therapeutics Inc. now has a market cap of $1.05 billion. Shares of Axsome Therapeutics Inc. have been trading within a range of $30.50 and $1.94 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.

Axsome Therapeutics Inc is a United States-based healthcare service provider. As a pre-clinical therapeutics developer, the company attends primarily to central nervous system disorders such as Alzheimer's. Its product portfolio consists of novel drugs like the AXS-02 (disodium zoledronate tetrahydrate), which is an oral, non-opioid therapeutic for chronic pain and the AXS-05, which is a fixed-dose combination of dextromethorphan and bupropion. The AXS-02 addresses pain in over three conditions, such as complex regional pain syndrome, knee osteoarthritis and chronic low back pain. The AXS-05 on the other hand, treats resistant depression and agitation in patients with Alzheimer's disease. Both the products have passed the preclinical, Phase 1 and Phase 2 stages of development.

Axsome Therapeutics Inc. is based out of New York, NY and has some 41 employees. Its CEO is Herriot Tabuteau.

For a complete fundamental analysis of Axsome Therapeutics Inc., check out Equities.com’s Stock Valuation Analysis report for AXSM.

Axsome Therapeutics Inc. is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

<<<
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.